SLA - Solagran Limited
- Thread starter yogi-in-oz
- Start date
-
- Tags
- sla solagran limited
The Board of Solagran Limited is pleased to announce that two Directors, Dr Vagif Soultanov
and Mr Charles Pellegrino, will depart today for a month in Russia and Hungary to lock in a
number of initiatives that will be key to the next stage of Solagran’s strategic development.
Dr Soultanov and Mr Pellegrino currently have nearly 60 meetings scheduled in Budapest
(11), St Petersburg (27), Moscow (11) and Tomsk/ Novosibirsk (10) with senior
representatives from the academic community, the medical profession, current and potential
strategic partners, as well as key decision-makers from government health and regulatory
authorities. Because of the likely impact of the use of Bioeffectives ® on both the health of the
population and the health budgets of different regions throughout Russia, they also plan to
meet with the Governors of St Petersburg and Novosibirsk.
and Mr Charles Pellegrino, will depart today for a month in Russia and Hungary to lock in a
number of initiatives that will be key to the next stage of Solagran’s strategic development.
Dr Soultanov and Mr Pellegrino currently have nearly 60 meetings scheduled in Budapest
(11), St Petersburg (27), Moscow (11) and Tomsk/ Novosibirsk (10) with senior
representatives from the academic community, the medical profession, current and potential
strategic partners, as well as key decision-makers from government health and regulatory
authorities. Because of the likely impact of the use of Bioeffectives ® on both the health of the
population and the health budgets of different regions throughout Russia, they also plan to
meet with the Governors of St Petersburg and Novosibirsk.
http://www.acnnewswire.net/press/en/36402/SOLAGRAN-LIMITED.html
Ok, I managed to get some on today's low, and wish me luck!
The main conference is next week I think, possibly the 16th and may be broadcast on boardroomradio.com., as they seem to love SLA.
Good luck to all.
Ok, I managed to get some on today's low, and wish me luck!
The main conference is next week I think, possibly the 16th and may be broadcast on boardroomradio.com., as they seem to love SLA.
Good luck to all.
Well if you aren't in by Wednesday you will miss a great opportunity by the sounds of things.
Bioeffective-A is being sold here already in Australia and has been doing extremely well apparently, and it sounds like Dr Soultinov has some magic potions, with more news to come over the next few years. Who would have thought we'd be relying on the Russians to cure the world of most of it's ills.
The train is leaving the station IMO.
Bioeffective-A is being sold here already in Australia and has been doing extremely well apparently, and it sounds like Dr Soultinov has some magic potions, with more news to come over the next few years. Who would have thought we'd be relying on the Russians to cure the world of most of it's ills.
The train is leaving the station IMO.
Stole this from another site
I've been re-reading Philip Fisher's investment classic Common Stocks and Uncommon Profits to see how his 15 criteria for picking great growth stocks relate to SLA.
(For those who haven't heard of him, Fisher was an American fund manager from the 1930s to the 1970s with a remarkable track record for picking great growth stocks and widely considered to be the father of the growth style of investing in much the same way Benjamin Graham and Warren Buffett are considered to be the fathers of the value style of investing.)
I'll run through Fisher's 15 points for picking great growth stocks one by one with my own comments on how I think SLA stacks up. I'd also really appreciate some comments and feedback from others who have been following the company for far longer than me and have researched it in far greater depth to see how they think SLA rates.
One final clarification before I begin, in Fisher's words " A company could well be an investment bonaza if it failed fully to qualify on a very few of them (ie a few of the 15 points). I do not think it could come up to my definition of a worthwhile investment if it failed to qualify on many."
1) Do the products have enough market potential to increase sales for the next few years?
I think we'd all agree a resounding yes !!!
2) Does management have the drive to continue increasing total sales through innovation?
Again a resounding yes! one only has to look at the R&D pipeline.
3) How effective is the conpany's R&D relative to its size?
Phenomenal !!!
4) Is the sales and marketing organization above-average?
Probably to early to tell, but the early signs are encouraging.
5) Does the company have good profit margins?
Although we don't know the exact profit margins at this stage, they should be very high.
6) How is the company improving profit margins?
SibEx acquisition and new methods for Ropren delivery are 2 significant examples.
7) Does the company treat workers well?
I'm not in a position to make an informed comment here. From my limited dealings with them, they appear to have a happy and motivated staff. Can Charles or anyone who has had more dealings with the company than me give some feedback?
8) Does the company treat executives well?
I think Fisher was referring to larger organisations than SLA here with many layers of management. Probably too early to tell here.
9) Does the company have a deep management bench?
A subjective call here, but IMHO Denis and Vagif with the help of Peter, Charles, Gene and Victor Roschin make a great management team. Too early to comment on the new appointments.
10) Does the company control cost and accounting well?
Exceptionally well!!!
11) Does the company stand out amongst competitors in any way (particular to industry)?
Does it what! Try treatments for previously incurable conditions and diseases without side effects !!!
12) Is the company long-range forward-looking?
Excellent strategic management looking forward a long way!
13) Is the company going to dilute shareholders excessively?
Refer to point 10. An exceptionally frugal management who have their interests aligned with shareholders.
14) Does the company speak freely of the good as well as the bad?
I'd appreciate some comments here from those who go back with the company longer than me. As far as I can tell in my dealings with them, and going on the open and frank way in which Denis and Vagif spoke and answered questions at the AGM, I'd say not a problem.
15) Does the management have unquestionable integrity? ( Fisher regarded this point as the most essential)
Again a subjective call, But IMHO an unequivocal yes!!!
So... to sum up, I think SLA passes Fisher's criteria for a potentially great growth stock with flying colours.
And that was posted 6 months ago....WOW
I've been re-reading Philip Fisher's investment classic Common Stocks and Uncommon Profits to see how his 15 criteria for picking great growth stocks relate to SLA.
(For those who haven't heard of him, Fisher was an American fund manager from the 1930s to the 1970s with a remarkable track record for picking great growth stocks and widely considered to be the father of the growth style of investing in much the same way Benjamin Graham and Warren Buffett are considered to be the fathers of the value style of investing.)
I'll run through Fisher's 15 points for picking great growth stocks one by one with my own comments on how I think SLA stacks up. I'd also really appreciate some comments and feedback from others who have been following the company for far longer than me and have researched it in far greater depth to see how they think SLA rates.
One final clarification before I begin, in Fisher's words " A company could well be an investment bonaza if it failed fully to qualify on a very few of them (ie a few of the 15 points). I do not think it could come up to my definition of a worthwhile investment if it failed to qualify on many."
1) Do the products have enough market potential to increase sales for the next few years?
I think we'd all agree a resounding yes !!!
2) Does management have the drive to continue increasing total sales through innovation?
Again a resounding yes! one only has to look at the R&D pipeline.
3) How effective is the conpany's R&D relative to its size?
Phenomenal !!!
4) Is the sales and marketing organization above-average?
Probably to early to tell, but the early signs are encouraging.
5) Does the company have good profit margins?
Although we don't know the exact profit margins at this stage, they should be very high.
6) How is the company improving profit margins?
SibEx acquisition and new methods for Ropren delivery are 2 significant examples.
7) Does the company treat workers well?
I'm not in a position to make an informed comment here. From my limited dealings with them, they appear to have a happy and motivated staff. Can Charles or anyone who has had more dealings with the company than me give some feedback?
8) Does the company treat executives well?
I think Fisher was referring to larger organisations than SLA here with many layers of management. Probably too early to tell here.
9) Does the company have a deep management bench?
A subjective call here, but IMHO Denis and Vagif with the help of Peter, Charles, Gene and Victor Roschin make a great management team. Too early to comment on the new appointments.
10) Does the company control cost and accounting well?
Exceptionally well!!!
11) Does the company stand out amongst competitors in any way (particular to industry)?
Does it what! Try treatments for previously incurable conditions and diseases without side effects !!!
12) Is the company long-range forward-looking?
Excellent strategic management looking forward a long way!
13) Is the company going to dilute shareholders excessively?
Refer to point 10. An exceptionally frugal management who have their interests aligned with shareholders.
14) Does the company speak freely of the good as well as the bad?
I'd appreciate some comments here from those who go back with the company longer than me. As far as I can tell in my dealings with them, and going on the open and frank way in which Denis and Vagif spoke and answered questions at the AGM, I'd say not a problem.
15) Does the management have unquestionable integrity? ( Fisher regarded this point as the most essential)
Again a subjective call, But IMHO an unequivocal yes!!!
So... to sum up, I think SLA passes Fisher's criteria for a potentially great growth stock with flying colours.
And that was posted 6 months ago....WOW
- Joined
- 11 March 2007
- Posts
- 4
- Reactions
- 0
Hey all,
It was I who actually dug those 15 points up(originally from another poster) to answer a question of whether SLA was still worth investing in, or had the boat been missed. IMO there is still alot of value in entering and holding. I originally got the tip on SLA in Nov 06, did all the research and initially entered in Dec 06. I wont be selling anytime soon as this R+D company is transitioning into a fully fledged Pharmacetical Company. But all natural, without side-efects.
With management in day-to-day contact with the Russian Ministry re Ropren Approval, and still confident of Approval by the end of May, it should be a great month. A worldwide partnership/lisceneing agreement will follow Approval with Big Pharma for Ropren for Liver disease. This will be absolutely massive IMO. And only one application!
Bio B sales will be rising, as will Bio A, just released. Bio A sales will rise dramatically when their market leading (one of) partner launches it under one of their well-known brands to chemists and health food stores around the country.
The BioProspect deal in Animal/Agri recently shows how much Bioeffectives are valued, and gives them more credibility IMO. BPO wouldnt be injecting millions in cash, 2(out of 5) board positions, and 25% of their company if they didnt think they were outstanding.
We are also waiting on trial results, which we always are due to the impressive planning and array of trials going on. The Russian alcho/drug addict trials of Bio A and R- "Will make the world sit up and listen" Vagif. 3 patents being finalised-?HIV,HepC,depression..Liposomal/injectable delivery systems for Ropren, Flu/Birdflu, Bio A for H.Pylori(gastric) to name a few.
My price target is $2.50 by AGM in Nov. I believe $10 by AGM 2008 is not unachievable as income increases dramatically with Ropren on the market.
Cheers to all holders!
BB
(there's a great forum on Sharescene.com for more chat)
It was I who actually dug those 15 points up(originally from another poster) to answer a question of whether SLA was still worth investing in, or had the boat been missed. IMO there is still alot of value in entering and holding. I originally got the tip on SLA in Nov 06, did all the research and initially entered in Dec 06. I wont be selling anytime soon as this R+D company is transitioning into a fully fledged Pharmacetical Company. But all natural, without side-efects.
With management in day-to-day contact with the Russian Ministry re Ropren Approval, and still confident of Approval by the end of May, it should be a great month. A worldwide partnership/lisceneing agreement will follow Approval with Big Pharma for Ropren for Liver disease. This will be absolutely massive IMO. And only one application!
Bio B sales will be rising, as will Bio A, just released. Bio A sales will rise dramatically when their market leading (one of) partner launches it under one of their well-known brands to chemists and health food stores around the country.
The BioProspect deal in Animal/Agri recently shows how much Bioeffectives are valued, and gives them more credibility IMO. BPO wouldnt be injecting millions in cash, 2(out of 5) board positions, and 25% of their company if they didnt think they were outstanding.
We are also waiting on trial results, which we always are due to the impressive planning and array of trials going on. The Russian alcho/drug addict trials of Bio A and R- "Will make the world sit up and listen" Vagif. 3 patents being finalised-?HIV,HepC,depression..Liposomal/injectable delivery systems for Ropren, Flu/Birdflu, Bio A for H.Pylori(gastric) to name a few.
My price target is $2.50 by AGM in Nov. I believe $10 by AGM 2008 is not unachievable as income increases dramatically with Ropren on the market.
Cheers to all holders!
BB
(there's a great forum on Sharescene.com for more chat)
- Joined
- 21 May 2007
- Posts
- 363
- Reactions
- 2
Good ann on patent application acceptance today. Have they had their run, or will this new ann keep them going?
- Joined
- 29 May 2007
- Posts
- 6
- Reactions
- 0
Anyone got ideas on recent slump. Hit 1.13 today. Just people getting tired of waiting for Roepren approval?
I hold SLA
I hold SLA
- Joined
- 29 May 2007
- Posts
- 6
- Reactions
- 0
Thats what I kind of thought hey. Patience is a virtue, and certainly one seldom exhibited by moi. I'm holding on though, slump doesn't really bother me, plenty of upside here.
- Joined
- 11 March 2007
- Posts
- 4
- Reactions
- 0
Cheers Irish Yup, one to hold onto this one. As recent sp movements have shown, can go up very very quickly. Recent retrace overdue, and good reason for it too. Fundamentals havent changed DJ. In fact, good to see another 1/2mil worth of shares in directors hands Its very unusual for the director of a Co to say they have NO INTENTION OF EVER SELLING!!! (Denis-BRR)
Yep, recent decrease most probably due to Ropren Approval delay...Russian Ministry of Health gave us the timeline though(April/May) not Solagran. Cant be far away, especially with Vagif and co over there now. Vagif gets back Wed i think, so time will tell...not if, but when
So Approval delay now built into sp, and we even saw a strengthening on Friday. I would imagine sp wouldnt drop too much more, probably stay in the range of 1.15-1.30 till approval IMO (thats if there's no other ann.). Could also track back up to 1.55 highs on expectation that Approval CANT be far away now...
With the mid to long term potential of this Co, a few cents here or there at the mo doesnt worry me..looking for multiple dollars sp, and dividends in not-too-distant future..
Cheers
BB
Yup, one to hold onto this one. As recent sp movements have shown, can go up very very quickly. Recent retrace overdue, and good reason for it too. Fundamentals havent changed DJ. In fact, good to see another 1/2mil worth of shares in directors hands Its very unusual for the director of a Co to say they have NO INTENTION OF EVER SELLING!!! (Denis-BRR)Yep, recent decrease most probably due to Ropren Approval delay...Russian Ministry of Health gave us the timeline though(April/May) not Solagran. Cant be far away, especially with Vagif and co over there now. Vagif gets back Wed i think, so time will tell...not if, but when
So Approval delay now built into sp, and we even saw a strengthening on Friday. I would imagine sp wouldnt drop too much more, probably stay in the range of 1.15-1.30 till approval IMO (thats if there's no other ann.). Could also track back up to 1.55 highs on expectation that Approval CANT be far away now...
With the mid to long term potential of this Co, a few cents here or there at the mo doesnt worry me..looking for multiple dollars sp, and dividends in not-too-distant future..
Cheers
BB
- Joined
- 23 February 2007
- Posts
- 165
- Reactions
- 0
i realy think that we are gonna see nice things here
directors are buying more...
and how will return end this week...
right the directors Dr Vagif Soultanov and Mr Charles Pellegrino
maybe they have something to share with us???
directors are buying more...
and how will return end this week...
right the directors Dr Vagif Soultanov and Mr Charles Pellegrino
maybe they have something to share with us???
- Joined
- 23 February 2007
- Posts
- 165
- Reactions
- 0
they sure did had some to share with us....
announce...out today...Upgrade to Bioeffective R Manufacturing Capacity
announce...out today...Upgrade to Bioeffective R Manufacturing Capacity
- Joined
- 23 February 2007
- Posts
- 165
- Reactions
- 0
does anyone know what our SLA is up to?
it's so quiet after the ann......
does annyone can come up with a support level
the +/-5 month uptrend and the current downtrend seems to hit an sp of about 1.2 somewhere by the end of june...
and hopefully should than pick up again
anyway i m a chartyrooki but believe in sla
cheers
it's so quiet after the ann......
does annyone can come up with a support level
the +/-5 month uptrend and the current downtrend seems to hit an sp of about 1.2 somewhere by the end of june...
and hopefully should than pick up again
anyway i m a chartyrooki but believe in sla
cheers
- Joined
- 1 January 2007
- Posts
- 317
- Reactions
- 1
Hey Guys, I hear there is an ann very soon? Anyone have any info on this? or maybe shead me some light... I know it's to do with the russia project but I thought we still had a while yet....
Thanks
I'm holding....
Thanks
I'm holding....
Yes the russian ministry has indicated that ropren will be approved in june (final approval as its already 99% approved anyway). they have pushed this date back a couple of times already but hopefully it will come through next week without any more delays.
